These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38697188)

  • 1. At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse.
    Parker C; Wood BM
    Soc Work; 2024 Jun; 69(3):297-302. PubMed ID: 38697188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin for treating substance use disorders?
    de Veen BT; Schellekens AF; Verheij MM; Homberg JR
    Expert Rev Neurother; 2017 Feb; 17(2):203-212. PubMed ID: 27684102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of psilocybin in depressive disorders.
    Najib J
    Curr Med Res Opin; 2024 Oct; 40(10):1793-1808. PubMed ID: 39177339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.
    Szafoni S; Gręblowski P; Grabowska K; Więckiewicz G
    Front Psychiatry; 2024; 15():1406888. PubMed ID: 38919636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
    Kozlowska U; Nichols C; Wiatr K; Figiel M
    J Neurochem; 2022 Jul; 162(1):89-108. PubMed ID: 34519052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics: Threshold of a Therapeutic Revolution.
    Heal DJ; Smith SL; Belouin SJ; Henningfield JE
    Neuropharmacology; 2023 Sep; 236():109610. PubMed ID: 37247807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing potential of psilocybin for depressive disorders.
    Kozak Z; Johnson MW; Aaronson ST
    Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.
    Sharma R; Batchelor R; Sin J
    J Psychoactive Drugs; 2023; 55(5):612-630. PubMed ID: 36933948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Up-to-Date on clinical and preclinical studies of psilocybin therapy].
    Ibi D
    Nihon Yakurigaku Zasshi; 2024; 159(4):214-218. PubMed ID: 38945903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelic Medicines in Major Depression: Progress and Future Challenges.
    Bouso JC; Ona G; Dos Santos RG; Hallak JEC
    Adv Exp Med Biol; 2021; 1305():515-533. PubMed ID: 33834416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
    Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
    Miceli McMillan R; Jordens C
    Med Health Care Philos; 2022 Jun; 25(2):225-237. PubMed ID: 35064398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
    Yaden DB; Berghella AP; Hendricks PS; Yaden ME; Levine M; Rohde JS; Nayak S; Johnson MW; Garcia-Romeu A
    Pharmacol Res; 2024 Jan; 199():106998. PubMed ID: 38029805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.